XML 59 R44.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Description of Business (Details) $ in Thousands | 12 Months Ended |
--- | --- | ---
Dec. 31, 2024 USD ($) designation patient site | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($)
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |
Cash, cash equivalents and restricted cash | $ 32,412 | $ 12,696 | $ 11,822
Short-term investments | 20,821 | 19,808 |
Cash used in operating activities | 18,681 | $ 31,251 |
Principal payments | 10,600 |  |
Accounts Payable Accrued Expenses And Lease Liabilities |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |
Current capital commitments | 6,100 |  |
Lease Liabilities |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |
Noncurrent capital commitments | 1,300 |  |
Third Party Settlement |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |
Noncurrent capital commitments | $ 800 |  |
HEPZATO KIT |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |
Number of orphan drug designations granted by FDA | designation | 6 |  |
Clinical trial, number of patients | patient | 90 |  |
Clinical trial, number of sites (more than) | site | 20 |  |
HEPZATO KIT | Minimum |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |
Addressable market for liver-dominant mCRC receiving third-line treatment, number of patients | patient | 6,000 |  |
HEPZATO KIT | Maximum |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |
Addressable market for liver-dominant mCRC receiving third-line treatment, number of patients | patient | 10,000 |  |
HEPZATO KIT, Melphalan |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |
Number of orphan drug designations granted by FDA | designation | 5 |  |
HEPZATO KIT, Doxorubicin |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |
Number of orphan drug designations granted by FDA | designation | 1 |  |

X
- Definition Addressable Market For Liver-Dominant mCRC Receiving Third Line Treatment, Number Of Patients + References No definition available. + Details
Name: | dcth_AddressableMarketForLiverDominantMCRCReceivingThirdLineTreatmentNumberOfPatients
Namespace Prefix: | dcth_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Capital commitments current. + References No definition available. + Details
Name: | dcth_CapitalCommitmentsCurrent
Namespace Prefix: | dcth_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Capital commitments non current. + References No definition available. + Details
Name: | dcth_CapitalCommitmentsNonCurrent
Namespace Prefix: | dcth_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Clinical Trial, Number Of Patients + References No definition available. + Details
Name: | dcth_ClinicalTrialNumberOfPatients
Namespace Prefix: | dcth_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Clinical Trial, Number Of Sites + References No definition available. + Details
Name: | dcth_ClinicalTrialNumberOfSites
Namespace Prefix: | dcth_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Orphan Drug Designations Granted by US Food and Drug Administration + References No definition available. + Details
Name: | dcth_NumberOfOrphanDrugDesignationsGrantedByUSFoodAndDrugAdministration
Namespace Prefix: | dcth_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Organization consolidation basis of presentation business description and accounting policies line item. + References No definition available. + Details
Name: | dcth_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesLineItems
Namespace Prefix: | dcth_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details
Name: | us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details
Name: | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_NetCashProvidedByUsedInOperatingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details
Name: | us-gaap_RepaymentsOfLongTermDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | dcth_CapitalCommitementsAxis=dcth_AccountsPayableAccruedExpensesAndLeaseLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dcth_CapitalCommitementsAxis=dcth_LeaseLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dcth_CapitalCommitementsAxis=dcth_ThirdPartySettlementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=dcth_HEPZATOKITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=dcth_HEPZATOKITMelphalanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=dcth_HEPZATOKITDoxorubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |